Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme primarily responsible for the regulation of intracellular cortisol levels. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Emerging literature also supports a...
Gespeichert in:
Veröffentlicht in: | Journal of medicinal chemistry 2014-06, Vol.57 (11), p.4466-4486 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4486 |
---|---|
container_issue | 11 |
container_start_page | 4466 |
container_title | Journal of medicinal chemistry |
container_volume | 57 |
creator | Scott, James S Goldberg, Frederick W Turnbull, Andrew V |
description | 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme primarily responsible for the regulation of intracellular cortisol levels. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Emerging literature also supports a potential role in the treatment of other unmet medical needs including Alzheimer’s disease, vascular inflammation, cardiovascular disease, and glaucoma. The aim of this article is to review the medicinal chemistry literature around small molecule approaches to developing synthetic inhibitors of 11β-HSD1 and to highlight key compounds that have resulted from the efforts of both industrial and academic groups. The reported data from 11β-HSD1 inhibitors that have progressed into the clinic are summarized followed by a perspective from the authors. |
doi_str_mv | 10.1021/jm4014746 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1535626580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1535626580</sourcerecordid><originalsourceid>FETCH-LOGICAL-a315t-94a7769f9ec91530cda670331d160a0f52b09c478a8efe262f6895a7bf2a60153</originalsourceid><addsrcrecordid>eNptkLFOwzAQhi0EoqUw8AIoC1I7BM6O7cQjaoFWAjFQBqbISWyaKqmLnUjktXgQnglXKZ2YTnf67pf-D6FLDDcYCL5d1xQwjSk_QkPMCIQ0AXqMhgCEhISTaIDOnFsDQIRJdIoGhBJBRcKG6P1ZFWVebmQVTFeqLl1ju8DoYLFZlVnZGOt2G8Y_3-G8K6z56lyjrCmLYKZWu8OH2kingmW3VQEOxj35OsOTc3SiZeXUxX6O0NvD_XI6D59eHhfTu6dQRpg1oaAyjrnQQuUCswjyQvIYoggXmIMEzUgGIqdxIhOllS-jeSKYjDNNJAf_MULjPndrzWerXJP6FrmqKrlRpnWpRxgnnCXg0UmP5tY4Z5VOt7aspe1SDOnOZHow6dmrfWyb1ao4kH_qPHDdAzJ36dq01jt0_wT9AkNoeHc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1535626580</pqid></control><display><type>article</type><title>Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)</title><source>MEDLINE</source><source>American Chemical Society (ACS) Journals</source><creator>Scott, James S ; Goldberg, Frederick W ; Turnbull, Andrew V</creator><creatorcontrib>Scott, James S ; Goldberg, Frederick W ; Turnbull, Andrew V</creatorcontrib><description>11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme primarily responsible for the regulation of intracellular cortisol levels. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Emerging literature also supports a potential role in the treatment of other unmet medical needs including Alzheimer’s disease, vascular inflammation, cardiovascular disease, and glaucoma. The aim of this article is to review the medicinal chemistry literature around small molecule approaches to developing synthetic inhibitors of 11β-HSD1 and to highlight key compounds that have resulted from the efforts of both industrial and academic groups. The reported data from 11β-HSD1 inhibitors that have progressed into the clinic are summarized followed by a perspective from the authors.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm4014746</identifier><identifier>PMID: 24294985</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>11-beta-Hydroxysteroid Dehydrogenase Type 1 - antagonists & inhibitors ; Alzheimer Disease - drug therapy ; Alzheimer Disease - enzymology ; Animals ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - enzymology ; Clinical Trials as Topic ; Glaucoma - drug therapy ; Glaucoma - enzymology ; Glucocorticoids - metabolism ; Humans ; Metabolic Syndrome - drug therapy ; Metabolic Syndrome - enzymology</subject><ispartof>Journal of medicinal chemistry, 2014-06, Vol.57 (11), p.4466-4486</ispartof><rights>Copyright © 2013 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a315t-94a7769f9ec91530cda670331d160a0f52b09c478a8efe262f6895a7bf2a60153</citedby><cites>FETCH-LOGICAL-a315t-94a7769f9ec91530cda670331d160a0f52b09c478a8efe262f6895a7bf2a60153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm4014746$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm4014746$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24294985$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scott, James S</creatorcontrib><creatorcontrib>Goldberg, Frederick W</creatorcontrib><creatorcontrib>Turnbull, Andrew V</creatorcontrib><title>Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme primarily responsible for the regulation of intracellular cortisol levels. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Emerging literature also supports a potential role in the treatment of other unmet medical needs including Alzheimer’s disease, vascular inflammation, cardiovascular disease, and glaucoma. The aim of this article is to review the medicinal chemistry literature around small molecule approaches to developing synthetic inhibitors of 11β-HSD1 and to highlight key compounds that have resulted from the efforts of both industrial and academic groups. The reported data from 11β-HSD1 inhibitors that have progressed into the clinic are summarized followed by a perspective from the authors.</description><subject>11-beta-Hydroxysteroid Dehydrogenase Type 1 - antagonists & inhibitors</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - enzymology</subject><subject>Animals</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - enzymology</subject><subject>Clinical Trials as Topic</subject><subject>Glaucoma - drug therapy</subject><subject>Glaucoma - enzymology</subject><subject>Glucocorticoids - metabolism</subject><subject>Humans</subject><subject>Metabolic Syndrome - drug therapy</subject><subject>Metabolic Syndrome - enzymology</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkLFOwzAQhi0EoqUw8AIoC1I7BM6O7cQjaoFWAjFQBqbISWyaKqmLnUjktXgQnglXKZ2YTnf67pf-D6FLDDcYCL5d1xQwjSk_QkPMCIQ0AXqMhgCEhISTaIDOnFsDQIRJdIoGhBJBRcKG6P1ZFWVebmQVTFeqLl1ju8DoYLFZlVnZGOt2G8Y_3-G8K6z56lyjrCmLYKZWu8OH2kingmW3VQEOxj35OsOTc3SiZeXUxX6O0NvD_XI6D59eHhfTu6dQRpg1oaAyjrnQQuUCswjyQvIYoggXmIMEzUgGIqdxIhOllS-jeSKYjDNNJAf_MULjPndrzWerXJP6FrmqKrlRpnWpRxgnnCXg0UmP5tY4Z5VOt7aspe1SDOnOZHow6dmrfWyb1ao4kH_qPHDdAzJ36dq01jt0_wT9AkNoeHc</recordid><startdate>20140612</startdate><enddate>20140612</enddate><creator>Scott, James S</creator><creator>Goldberg, Frederick W</creator><creator>Turnbull, Andrew V</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140612</creationdate><title>Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)</title><author>Scott, James S ; Goldberg, Frederick W ; Turnbull, Andrew V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a315t-94a7769f9ec91530cda670331d160a0f52b09c478a8efe262f6895a7bf2a60153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>11-beta-Hydroxysteroid Dehydrogenase Type 1 - antagonists & inhibitors</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - enzymology</topic><topic>Animals</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - enzymology</topic><topic>Clinical Trials as Topic</topic><topic>Glaucoma - drug therapy</topic><topic>Glaucoma - enzymology</topic><topic>Glucocorticoids - metabolism</topic><topic>Humans</topic><topic>Metabolic Syndrome - drug therapy</topic><topic>Metabolic Syndrome - enzymology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scott, James S</creatorcontrib><creatorcontrib>Goldberg, Frederick W</creatorcontrib><creatorcontrib>Turnbull, Andrew V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scott, James S</au><au>Goldberg, Frederick W</au><au>Turnbull, Andrew V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2014-06-12</date><risdate>2014</risdate><volume>57</volume><issue>11</issue><spage>4466</spage><epage>4486</epage><pages>4466-4486</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme primarily responsible for the regulation of intracellular cortisol levels. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Emerging literature also supports a potential role in the treatment of other unmet medical needs including Alzheimer’s disease, vascular inflammation, cardiovascular disease, and glaucoma. The aim of this article is to review the medicinal chemistry literature around small molecule approaches to developing synthetic inhibitors of 11β-HSD1 and to highlight key compounds that have resulted from the efforts of both industrial and academic groups. The reported data from 11β-HSD1 inhibitors that have progressed into the clinic are summarized followed by a perspective from the authors.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>24294985</pmid><doi>10.1021/jm4014746</doi><tpages>21</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 2014-06, Vol.57 (11), p.4466-4486 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_1535626580 |
source | MEDLINE; American Chemical Society (ACS) Journals |
subjects | 11-beta-Hydroxysteroid Dehydrogenase Type 1 - antagonists & inhibitors Alzheimer Disease - drug therapy Alzheimer Disease - enzymology Animals Cardiovascular Diseases - drug therapy Cardiovascular Diseases - enzymology Clinical Trials as Topic Glaucoma - drug therapy Glaucoma - enzymology Glucocorticoids - metabolism Humans Metabolic Syndrome - drug therapy Metabolic Syndrome - enzymology |
title | Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T09%3A41%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medicinal%20Chemistry%20of%20Inhibitors%20of%2011%CE%B2-Hydroxysteroid%20Dehydrogenase%20Type%201%20(11%CE%B2-HSD1)&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Scott,%20James%20S&rft.date=2014-06-12&rft.volume=57&rft.issue=11&rft.spage=4466&rft.epage=4486&rft.pages=4466-4486&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/jm4014746&rft_dat=%3Cproquest_cross%3E1535626580%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1535626580&rft_id=info:pmid/24294985&rfr_iscdi=true |